Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eururo.2022.08.005
PubMed Identifier: 36055895
Publication URI: http://europepmc.org/abstract/MED/36055895
Type: Journal Article/Review
Volume: 83
Parent Publication: European urology
Issue: 1
ISSN: 0302-2838